Business Description
Amcad Biomed Corp
ISIN : TW0004188008
Total Employee Number:
34Description
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 78.15 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17.4 | |||||
Beneish M-Score | -2.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -24.8 | |||||
3-Year EBITDA Growth Rate | -9.2 | |||||
3-Year EPS without NRI Growth Rate | 3.8 | |||||
3-Year FCF Growth Rate | -5.6 | |||||
3-Year Book Growth Rate | 1.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.75 | |||||
9-Day RSI | 24.36 | |||||
14-Day RSI | 29.28 | |||||
3-1 Month Momentum % | -8.05 | |||||
6-1 Month Momentum % | -24.13 | |||||
12-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.62 | |||||
Quick Ratio | 21.11 | |||||
Cash Ratio | 20.48 | |||||
Days Inventory | 520.43 | |||||
Days Sales Outstanding | 159.15 | |||||
Days Payable | 41.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | 0.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.93 | |||||
Operating Margin % | -288.97 | |||||
Net Margin % | -183.06 | |||||
EBITDA Margin % | -182.4 | |||||
FCF Margin % | -156.92 | |||||
OCF Margin % | -154.62 | |||||
ROE % | -10.34 | |||||
ROA % | -8.54 | |||||
ROIC % | -34.86 | |||||
3-Year ROIIC % | -72.85 | |||||
ROC (Joel Greenblatt) % | -67.49 | |||||
ROCE % | -11.3 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 19.65 | |||||
PB Ratio | 1.16 | |||||
Price-to-Tangible-Book | 1.3 | |||||
EV-to-EBIT | -4.36 | |||||
EV-to-EBITDA | -5.61 | |||||
EV-to-Revenue | 10.23 | |||||
EV-to-FCF | -7.38 | |||||
Price-to-GF-Value | 1.04 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Price-to-Net-Cash | 2.22 | |||||
Earnings Yield (Greenblatt) % | -22.92 | |||||
FCF Yield % | -7.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amcad Biomed Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 30.437 | ||
| EPS (TTM) (NT$) | -0.882 | ||
| Beta | 0.2017 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.55 | ||
| Volatility % | 15.98 | ||
| 14-Day RSI | 29.28 | ||
| 14-Day ATR (NT$) | 0.342128 | ||
| 20-Day SMA (NT$) | 10.161 | ||
| 12-1 Month Momentum % | -30 | ||
| 52-Week Range (NT$) | 9.06 - 17.2 | ||
| Shares Outstanding (Mil) | 63.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amcad Biomed Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amcad Biomed Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amcad Biomed Corp Frequently Asked Questions
What is Amcad Biomed Corp(ROCO:4188)'s stock price today?
The current price of ROCO:4188 is NT$9.45. The 52 week high of ROCO:4188 is NT$17.20 and 52 week low is NT$9.06.
When is next earnings date of Amcad Biomed Corp(ROCO:4188)?
The next earnings date of Amcad Biomed Corp(ROCO:4188) is .
Does Amcad Biomed Corp(ROCO:4188) pay dividends? If so, how much?
Amcad Biomed Corp(ROCO:4188) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Amcad Biomed Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers